6 Experimental Alzheimers Disease Diagnostics Projects Get Funding Boost
Summary
On Wednesday the New York-based Alzheimer’s Drug Discovery Foundation (ADDF) named six scientists who will receive a cut of $6 million to put toward their work developing diagnostic tools for the disease. A second set, the six grants revealed Wednesday, are supporting diagnostic blood tests in various stages of development, including one of the most advanced, as well as a potential detection method using retinal imaging technology. The test, in collaboration with Roche, aims to measure fragments of certain protein that, in excess, form amyloid plaques, one of the hallmark pathological signs of the disease. Samuil Umansky, co-founder, chief scientific officer and president at DiamiR Biosciences in New Jersey, was awarded $492,000 to put toward a test measuring certain microRNAs, specific small molecules that it has identified as associated with neurodegeneration and inflammation. Galasko, working with scientists at ADx Neurosciences in Belgium, aims to develop a blood test that measures tau, the other pathological hallmark of Alzheimer’s disease, and NfL, at very low concentrations, with single molecule immunoassays.
Classifications
AskAI Classifications
LabelsLinked Companies
